Skip to main content
  • Preliminary BIOSOLVE-IV registry analysis shows low TLF rate for Magmaris stent

    An analysis of the first 600 patients in the BIOSOLVE-IV registry confirms low target lesion failure rates of the Magmaris stent shown in previous trials, according to late-breaking trial results presented Monday at Cardiovascular Research Technologies (CRT) 2019.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details